We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Sanofi and Regeneron Give Up on Kevzara for COVID-19 After Phase 3 Flop

Sanofi and Regeneron Give Up on Kevzara for COVID-19 After Phase 3 Flop

September 2, 2020

Sanofi and Regeneron Pharmaceuticals said they have no plans to conduct further trials of their rheumatoid arthritis drug Kevzara for COVID-19 after it failed in a late-stage study.

The phase 3 trial tested 200-mg or 400-mg doses of Kevzara (sarilumab) vs. a placebo in 420 severely or critically ill COVID-19 patients. The benefits from the treatment, including shorter hospital stays and faster improvements in clinical outcomes, were not statistically significant, and some patients experienced serious adverse events, including pneumonia.

In July, the companies stopped a separate phase 3 U.S. trial of the immunosuppressive drug as a treatment for critically ill COVID-19 patients following disappointing results (DID, July 6).

Roche’s Actemra (tocilizumab), another rheumatoid arthritis treatment, was also found to have no benefit for hospitalized COVID-19 patients with severe pneumonia in a phase 3 trial. However, the drug is still in multiple mid- and late-stage trials for COVID-19, including as a  combination treatment with Gilead Sciences’ remdesivir (DID, July 30).

Eli Lilly’s rheumatoid arthritis drug Olumiant (baricitinib) is also in phase 3 testing for hospitalized COVID-19 patients and is also under evaluation with remdesivir. Results of those trials have not yet been released (DID, June 16). — Jordan Williams

COVID-19

Upcoming Events

  • 15Apr

    Five Telltale Signs You’re Ready for an Electronic TMF System

  • 21Apr

    CDER’s Most Significant Guidance Priorities for 2021: Biosimilars/Biologics, Generics/Exclusivity, Real-World Evidence, Drug Development and Digital Health

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

  • 06May

    The World of Post-COVID-19 Clinical Trials: How to Prepare for What’s Coming Next

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • Bristol Myers Squibb logo

    UK’s NICE Rejects Opdivo and Yervoy Combo for Lung Cancer

  • ClearanceStamp_Orange.gif

    Medtronic Earns De Novo Clearance for AI Colonoscopy System

  • HealthCanada_Logo.gif

    Health Canada Introduces New Reporting Requirements to Reduce Shortages

  • Gilead_Logo.gif

    Gilead Halts Phase 3 Remdesivir Study in High-Risk Nonhospitalized COVID-19 Patients

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing